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Objective: To evaluate cartilage diffusion and isolated chondrocyte association of micelles and liposomes
and to determine the effect of cell-penetrating peptide (CPP) surface functionalization and extracellular
matrix depletion on chondrocyte association and cartilage diffusion, respectively.
Methods: Rhodamine-labeled micelles and liposomes were incubated with bovine chondrocytes and cell-
associated ﬂuorescence was quantiﬁed using ﬂow cytometry. Rhodamine-labeled CPP-modiﬁed micelles
and liposomes were incubated with chondrocytes and cell-associated ﬂuorescence was compared to
unmodiﬁed nanocarriers. Rhodamine-labeled micelles and liposomes were incubated with bovine
cartilage explants for 1, 2 and 4 h and cartilage-associated ﬂuorescence was compared across groups.
Cartilage explants were treated with interleukin-1 alpha (IL-1a) or with 0.25% trypsin. Rhodamine-
labeled micelles and liposomes were incubated with control, IL-1 and trypsin-treated explants and
cartilage-associated ﬂuorescence was compared across groups.
Results: Chondrocyte-associated ﬂuorescence following treatment with micelles was signiﬁcantly higher
(P < 0.001) than ﬂuorescence in the cells treated with liposomes while there was no difference between
cell-associated ﬂuorescence in the liposomes-treated and untreated controls. CPP-modiﬁed nanocarriers
exhibited a signiﬁcant increase in chondrocyte association compared to unmodiﬁed nanocarriers
(P < 0.001). Micelles exhibited a time and concentration-dependent diffusion in cartilage explants while
liposomes showed no diffusion. Following IL-1 and trypsin treatments, micelle diffusion in articular
cartilage was signiﬁcantly higher (P < 0.001) than their diffusion in untreated explants.
Conclusion: Micelles exhibit superior association with isolated chondrocytes compared to liposomes.
Surface modiﬁcation with a CPP enhances chondrocyte association of both nanocarriers. 15 nm diameter
micelles are better than 138 nm diameter liposomes in penetrating articular cartilage and extracellular
matrix depletion enhances micelle penetration.
 2012 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Owing to the involvement of a single or few joints, osteoarthritis
(OA) is an ideal disease for localized drug delivery. The biggest
challenge facing intra-articular (IA) drug administration in OA is the
short residence time of drugs following IA injection. It is estimated
that the joint ﬂuid half-life of small drug molecules, e.g., non-
steroidal anti-inﬂammatory drugs (NSAIDs) and large polymeric
molecules e.g., hyaluronic acid and recombinant proteins are in the
order of hours1,2,3,4,5. Pharmaceutical nanocarriers e.g., micelles and: K.A. Elsaid, Department of
armacy and Health Sciences,
-401-575-6137.
aid).
s Research Society International. Pliposomes are ﬂexible platforms for target tissue speciﬁc delivery of
drugs and imaging modalities6,7,8,9. Given their potential, these
nanocarriers could be used to enhance target joint tissue uptake of
disease-modifying anti-osteoarthritis drugs (DMOADs).
The objectives of this study are to compare the time and
concentration-dependent association of micelles and liposomes
with articular chondrocytes and diffusion in cartilage explants, to
examine the impact of early degenerative changes on their cartilage
diffusivity and the impact of surface modiﬁcation with a cell-
penetrating peptide (CPP) on chondrocyte association. We
hypothesized that micelles and liposomes would exhibit a time and
concentration-dependent association with chondrocytes and
cartilage tissue. Additionally, glycosaminoglycans (GAG) depletion
would lead to an enhancement of nanocarrier cartilage diffusion
and that nanocarrier surface modiﬁcation with a CPP would result
in enhanced chondrocyte association.ublished by Elsevier Ltd. All rights reserved.
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Rhodamine-labeled pharmaceutical nanocarrier preparation,
characterization, and CPP modiﬁcation
Liposomes and micelles were prepared by the thin ﬁlm hydra-
tion method. The liposomal formulation consisted of phosphatidyl-
choline (PC), cholesterol, and rhodamine-phosphatidylethanolamine
(rhodamine-PE) in a molar ratio 69:30:0.27 while the micelle
formulation consisted of methoxy (polyethylene glycol)-2000
(PEG-2K) and rhodamine-PE in a molar ratio of 99.5:0.5. Required
amounts of lipids for each formulation were aliquoted from chlo-
roform stock solutions and combined in a test tube. The chloroform
was evaporated under reduced pressure at 40C in a rotary evap-
orator to produce the dry lipid ﬁlm that was then hydrated with an
appropriate amount of phosphate buffered saline (pH 7.4). The
resulting crude lipid suspension was subjected to probe sonication
in 15e30 s pulses for no more than 5 min to produce the ﬁnal
preparations. The liposomes preparation had a ﬁnal total
phospholipid/cholesterol concentration of 5 mg/ml while the
micelles had a ﬁnal PEG-functionalized PE concentration of 5 mg/
ml. The ﬂuorescence intensities of a 1:100 dilution of the micelles
and liposomes at 5 mg/ml concentration were determined using a
Hitachi Fluorospec 2000 spectrophotometer with an excitation/
emissionwavelengths of 575/595 nmandwere compared to conﬁrm
that the preparations had equivalent ﬂuorescence intensities. The
HIV derived transactivator of transduction (TAT) peptidewas used as
a representative CPP for this study. To enable the preparation of CPP-
modiﬁed carriers, DSPE-PEG 2K-TATwas synthesized using a slightly
modiﬁed version of a previously described protocol10. Brieﬂy, 1,2-
distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide(poly-
ethylene glycol)-2000] (ammonium salt) (DSPE-PEG (2000)
maleimide) and TAT peptide (FITC-YGRKKRRQRRR-C) were dissolved
separately in a buffer solution (50 mM triethanolamine hydro-
chloride, 50 mM sodium phosphate, 150mMNaCl, and 1mM EDTA,
pH 8). An aliquot of TAT peptide solution containing 1mg of peptide
was combined in an amber scintillation vial with sufﬁcient DSPE-
PEG (2000) maleimide stock solution to yield a mixture with a
2-fold molar excess of TAT over the DSPE-PEG (2000) maleimide.
The mixture was stirred overnight at 4C. The DSPE-PEG (2000)-
TAT peptide solution was then dialyzed overnight against PBS at
4C under constant stirring using Spectra/Pro dialysis membrane
MWCO 6e8,000. Retention of FITC ﬂuorescence after dialysis was
used as a preliminary check that conjugation was successful fol-
lowed by conﬁrmation by TLC on silica plates using chlor-
oform:methanol 80:20 v/v as mobile phase. Dry lipid ﬁlms of the
appropriate amounts of lipids were then hydrated with an appro-
priate amount of the aqueous DSPE-PEG (2000)-TAT peptide stock
solution to yield either CPP-modiﬁed liposome or micelle prepa-
rations with 2.5 mg/ml total lipid and 2 mol % DSPE-PEG (2000)-
TAT. Characterization of the different preparations was performed
using dynamic light scattering.
Bovine articular cartilage explants harvesting and chondrocyte
isolation
Full-thickness bovine cartilage explants were drilled from the
medial and lateral sides of the femoral condyles of skeletally-mature
young animals, obtained from a local slaughterhouse, with no gross
signs of cartilage degeneration. The animals were 20e30 months of
age.Wehave harvested a total of 155 explants from18 animals for the
purpose of our experiments. The two hind knee joints of each animal
were used to harvest the explants at each harvest date. The explants
yield varied from 6 to 13 per harvest. All explants were 12 mm in
diameter and consistently less than1mm in thickness. Explantswerewashed repeatedly with sterile phosphate-buffered saline and
cultured in Dulbecco’s Modiﬁed Eagle’s Medium (DMEM) supple-
mented with 10% fetal bovine serum and 1% penicillin/streptomycin
at 37C and 5% CO2. Prior to conducting the tissue diffusion experi-
ments, explants were embedded in 1% sterile agarose to prevent
movement of the explants in the wells of the culture plates.
To isolate chondrocytes, cartilage slices from the tibial plateau
and the femoral condyles were ﬁnely sliced and incubated with
sterile 1 mg/ml collagenase from clostridium histolyticum (Sigma
Aldrich, USA) in serum-free DMEM for 5 h to overnight at 37Cwith
shaking. The cell suspension was then passed through a 70-mm cell
strainer (BD Biosciences, USA) to remove tissue debris and chon-
drocytes were pelleted by centrifugation at 1,500 rpm for 5 min.
The cell pellet was washed twice using DMEM þ 10% FBS and
resuspended chondrocytes were seeded at 500,000 cells/well using
12-well culture plates (Costar, USA). Bovine chondrocytes were
cultured in a monolayer and nanocarrier association experiments
were performed within 7 days of plating the cells.
Incubation of unmodiﬁed and CPP-modiﬁed micelles and liposomes
with bovine chondrocytes, ﬂow cytometry and assessment of
cytotoxicity
Rhodamine-labeled micelles and liposomes were incubated
with bovine chondrocyte cultures at 0.5 mg/ml for 1, 2 and 4 h at
37C. Following incubation, cells were harvested from culture wells
by trypsinization. Chondrocytes were incubated with 0.25% trypsin
(500 ml per well for 10 min at 37C). Trypsinization was terminated
by adding 1 ml of DMEM þ 10% FBS to each well and three wells
were pooled together, centrifuged at 1,500 rpm for 5 min and the
cell pellet was washed with DMEMþ10% FBS followed by PBS. Cells
were ﬁxed using 1% paraformaldehyde and cell-associated ﬂuo-
rescence was quantiﬁed using ﬂow cytometry with 488 nm exci-
tation laser with a 585/42 nm emission ﬁlter. In a separate set of
experiments, CPP-modiﬁed or unmodiﬁed micelles and liposomes
were incubated with bovine chondrocyte culture at 0.5 mg/ml for
1 h and cell harvest and analysis was performed as described above.
The reported mean values of chondrocyte-associated ﬂuorescence
intensities across treatments represent two independent experi-
ments with chondrocytes isolated from cartilage tissue of a total of
four unique animals with an n ¼ 3 (each “n” represents the pooling
of three wells) for each treatment at each time point.
Assessment of the cytotoxic effect of unmodiﬁed or CPP-
modiﬁed micelles and liposomes was performed by incubating
the four preparations at 0.5 mg/ml with bovine chondrocytes
(500,000 cells per ml; 100 ml per well) for 24 h at 37C in sterile 96-
well plates. Cell viability was determined colorimetrically using the
Aqueous One cell proliferation assay (Promega, USA). Data is pre-
sented as mean percentage cell viability  standard deviation (SD)
compared to untreated control. The data represent an average of
two independent assays, each with six replicates per plate.
Interleukin-1 alpha (IL-1a) and trypsin treatments of bovine
cartilage explants
Bovine cartilage explants were incubated with recombinant
human IL-1a (R & D systems, USA) to a ﬁnal concentration of 5 ng/ml
in serum-free DMEM þ 1% penicillin/streptomycin for 7 days with
IL-1 supplementation and media changes every 2e3 days. The
release of GAG from cartilage explants was determined using the
dimethylmethylene blue (DMMB) dye binding assay as described11.
Histological evaluation of IL-1 stimulated explants was performed
using Alcian blue staining and was used to conﬁrm GAG depletion
from the extracellular matrix. Trypsin treatment was performed
using 0.25% trypsin (3 ml per well) for 40 min at 37C.
A1 Hour 2 Hour 4 Hour
G
eo
m
e
tri
c 
M
e
a
n
 
o
f F
lu
or
e
sc
e
n
ce
0
2
4
6
8
10
12
14
16
18
20
Control
Liposomes
Micelles
*
**
***
B
Control
Liposomes 
Micelles
DIC Hoechst Rhodamine
Fig. 1. Association of rhodamine-labeled micelles and liposomes with bovine chon-
drocytes. A: Flow cytometry analysis of chondrocyte-associated ﬂuorescence following
incubation with micelles or liposomes at 0.5 mg/ml for 1, 2 and 4 h at 37C. Data
represent geometric mean  S.D. *Indicates that ﬂuorescence intensity in the 1-h
micelle-treated cells was signiﬁcantly higher (P < 0.001) than liposome-treated and
control cells. **Indicates that ﬂuorescence intensity in the 2-h micelle-treated cells was
signiﬁcantly higher (P < 0.001) than liposome-treated and control cells. ***Indicates
that ﬂuorescence intensity in the 4-h micelle-treated cells was signiﬁcantly higher
(P < 0.001) than liposome-treated and control cells. B: Representative micrographs of
rhodamine-labeled carriers association with chondrocytes. Top row: untreated chon-
drocytes (control). Middle row: chondrocytes incubated with rhodamine-labeled
liposomes at 0.125 mg/ml for 1 h. Bottom row: chondrocytes incubated with
rhodamine-labeled micelles at 0.125 mg/ml for 1 h. Left column: DIC light micrographs
visualizing cell morphology. Middle column: ﬂuorescence micrographs visualizing
Hoechst staining of cell nuclei. Right column: ﬂuorescence micrographs visualizing
cell-associated rhodamine ﬂuorescence.
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and trypsin-treated cartilage explants
Studies of time-dependent association of rhodamine-labeled
nanocarriers were performed using 0.5 mg/ml with 1, 2 and 4 h
incubations. Studies of concentration-dependent association of
micelles with native articular cartilage explants were performed
using 0.5, 0.28 and 0.0625 mg/ml with 1 h incubation. Following
IL-1a or trypsin treatment, rhodamine-labeled micelles and lipo-
somes, both at 0.5 mg/ml concentration, were incubated with
cartilage explants for 1 and 4 h, respectively. Following incubations,
explants were rinsed with DMEM to remove unbound nanocarriers
and subsequently prepared for cryosectioning. Serial cartilage
sections (10 mm) were obtained and imaged using a Nikon Eclipse
E600 ﬂuorescence microscope. Analysis of digital ﬂuorescence
micrographs was performed using Image J software. At least three
sections were evaluated per cartilage explant and ﬂuorescence
intensities from a standard region of interest (ROI) were averaged
across sections. Control cartilage explants were used to adjust for
cartilage auto-ﬂuorescence.
Statistical analyses
Absolute ﬂuorescence intensities of nanocarrier association
with articular cartilage were initially tested for equal variance and
normality. The ﬂuorescence intensities from different treatments
were normally distributed, but had different variances. When
applicable, mean values were reported with 95% conﬁdence
interval (CI). Chondrocyte association data is presented as mean
geometric ﬂuorescence  SD. The 12 explants of any experimental
group were derived from a range of 3e7 unique animals. A
generalized estimating equation for Gaussian-distributed data in
a cell means model was used to model ﬂuorescence intensities as
a function of experimental group while accounting for within-
animal nesting of explants. Different cell types were permitted to
have differing variances and further model misspeciﬁcation was
adjusted for using classical sandwich estimation. All hypotheses
were tested using orthogonal linear estimates, with alpha main-
tained across all comparisons at 0.05 using the HolmeShaffer step-
down approach, with adjusted P-values used to draw inferences.
This model was performed using SAS version 9.12. Chondrocyte
association data were analyzed using t-test for normally-
distributed or Whitney Rank-Sum for non-normally-distributed
data for 2-group comparisons and analysis of variance (ANOVA)
for normally-distributed or ANOVA on the ranks for non-normally
distributed data for multiple group comparison. This analysis was
performed using Sigma Plot, version 11.
Results
Size distribution of unmodiﬁed and CPP-modiﬁed micelles and
liposomes
The mean effective diameter of unmodiﬁed micelles was 15 nm
with a polydispersity index of 0.4 compared to a mean effective
diameter of 106 nm and a polydispersity index of 0.3 in the CPP-
modiﬁed micelles. The mean effective diameter of unmodiﬁed
liposomes was 138 nm and a polydispersity index of 0.2 compared
to a mean effective diameter of 397 nm and a polydispersity index
of 0.4 in the CPP-modiﬁed liposomes.
Association of micelles and liposomes with bovine chondrocytes and
effect of CPP-modiﬁcation
Association of rhodamine-labeled micelles and rhodamine-
labeled liposomes with bovine chondrocytes is presented inFig. 1(A). Following 1, 2 and 4 h incubations, chondrocytes treated
with micelles showed signiﬁcantly higher (P < 0.001) mean
geometric ﬂuorescence compared to liposomes-treated and
untreated chondrocytes. There were no signiﬁcant differences in
the geometric means of ﬂuorescence between the liposomes-
treated and untreated chondrocytes. There were no signiﬁcant
differences among geometric means of ﬂuorescence in the 1, 2 and
4 h micelles-treated chondrocytes. Similarly, there were no signif-
icant differences among geometric means of ﬂuorescence in the 1, 2
and 4 h liposomes-treated chondrocytes. The differential associa-
tion abilities of micelles and liposomes with chondrocytes are
shown qualitatively in Fig. 1(B). Following treatment with
0.125 mg/ml rhodamine-labeled micelles, chondrocyte-associated
ﬂuorescence was higher compared to chondrocytes treated with
0.125 mg/ml rhodamine-labeled liposomes.
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modiﬁcation on liposome association with chondrocytes is
shown in Fig. 2(A). The shift in the ﬂuorescence histogram of CPP-
modiﬁed liposomes compared to unmodiﬁed liposomes indicates
an increase in chondrocyte association as a consequence of
CPP modiﬁcation. Similarly, a shift in the ﬂuorescence histogram of
CPP-modiﬁed micelles compared to unmodiﬁed micelles was also
observed [Fig. 2(B)]. The mean geometric ﬂuorescence of CPP-
modiﬁed liposomes was 81.0  24.0 compared to 10.5  2.5 in
unmodiﬁed liposomes. The mean geometric ﬂuorescence of CPP-
modiﬁed micelles was 64.7  9.3 compared to 19.1  0.5 in
unmodiﬁed micelles. Fold changes in geometric ﬂuorescence ofFig. 2. Impact of CPP surface modiﬁcation of rhodamine-labeled carriers on their
ability to associate with bovine chondrocytes. A: Representative ﬂow cytometry
histograms showing cell-associated ﬂuorescence following treatment with unmodiﬁed
liposomes (blue), CPP-modiﬁed liposomes (green) or untreated cells (red). B: Repre-
sentative ﬂow cytometry histograms showing cell-associated ﬂuorescence following
treatment with unmodiﬁed micelles (blue), CPP-modiﬁed micelles (green) or
untreated cells (red). C: Fold change of geometric mean of cell-associated ﬂuorescence
following 1-h treatment with 0.5 mg/ml of each of unmodiﬁed liposomes, CPP-
modiﬁed liposomes, unmodiﬁed micelles and CPP-modiﬁed micelles compared to
untreated controls. Data represent geometric mean  S.D. *Indicates that fold change
in cell-associated ﬂuorescence following treatment with CPP-modiﬁed liposomes was
signiﬁcantly higher (P ¼ 0.002) than cell-associated ﬂuorescence with unmodiﬁed
liposomes treatment. **Indicates that fold change in cell-associated ﬂuorescence
following treatment with CPP-modiﬁed micelles was signiﬁcantly higher (P < 0.001)
than cell-associated ﬂuorescence of unmodiﬁed micelles, CPP-modiﬁed liposomes and
unmodiﬁed liposomes.unmodiﬁed and CPP-modiﬁed micelles and liposomes-treated
chondrocytes compared to untreated cells is presented in
Fig. 2(C). Fold change in chondrocyte-associated ﬂuorescence
following treatment with CPP-modiﬁed liposomes was signiﬁ-
cantly higher (P ¼ 0.002) than cell-associated ﬂuorescence
following unmodiﬁed liposomes treatment. Likewise, fold change
in chondrocyte-associated ﬂuorescence following treatment with
CPP-modiﬁed micelles was signiﬁcantly higher (P < 0.001) than
cell-associated ﬂuorescence subsequent to treatment with
unmodiﬁed micelles, CPP-modiﬁed liposomes as well as unmodi-
ﬁed liposomes. Finally, the chondrocyte viability following treat-
ment with unmodiﬁed micelles was 93.2  0.8% compared to
100.7  2.4% in CPP-modiﬁed micelles. The chondrocyte viability
following treatment with unmodiﬁed liposomes was 99.6  3.0%
compared to 97.0  2.0% in CPP-modiﬁed liposomes.
Diffusion of micelles and liposomes in bovine cartilage explants
Association of rhodamine-labeled micelles and liposomes with
native cartilage explants is presented in Fig. 3(A) (n ¼ 12 in each
group at each time point). At 1 h, micelles-treated explants
exhibited signiﬁcantly higher (P< 0.001) ﬂuorescence compared to
liposomes-treated explants. The mean ﬂuorescence intensity in the
micelles group was 10.0; 95% CI (7.2e12.7) compared to mean
ﬂuorescence intensity in the liposomes group of 3.9; 95% CI (3.0e
4.8). At 2 h, micelles-treated explants exhibited signiﬁcantly
higher (P ¼ 0.004) ﬂuorescence compared to liposomes-treated
explants. The mean ﬂuorescence intensity in the micelles group
was 16.4; 95% CI (11.0e20.7) compared to a mean ﬂuorescence
intensity in the liposomes group of 3.0; 95% CI (1.6e4.4). At 4 h,
micelles-treated explants exhibited signiﬁcantly higher (P < 0.001)
ﬂuorescence compared to liposomes-treated explants. The mean
ﬂuorescence intensity in themicelles groupwas 16.4; 95% CI (12.2e
20.7) compared to mean ﬂuorescence intensity in the liposomes
group of 4.5; 95% CI (3.4e5.7). The ﬂuorescence intensity of the 4-h
micelle incubationwas signiﬁcantly higher (P¼ 0.015) compared to
the ﬂuorescence intensity of the 1-h micelle incubation. There was
no signiﬁcant difference between the ﬂuorescence intensities of the
1 and 2-h micelles treatments (P ¼ 0.362) or between the ﬂuo-
rescence intensities between the 2 and 4-h treatments (P ¼ 0.838).
Fluorescence intensities in the 1-h incubation with 0.28 mg/ml
and 0.0625 mg/ml micelles were normalized to the mean ﬂuores-
cence intensity in the 1 h incubation with 0.5 mg/ml micelles
[Fig. 3(B)] (n ¼ 12 in each group). Compared to the 0.5 mg/ml
concentration, the 0.28 mg/ml concentration normalized ﬂuores-
cence was 77.8%; 95% CI (57.6e97.9), while the 0.0625 mg/ml
concentration normalized ﬂuorescence was 57.3%; 95% CI (51.7e
62.9). The cartilage-associated ﬂuorescence in the 0.0625 mg/ml
group was signiﬁcantly lower (P ¼ 0.003) than the cartilage-
associated ﬂuorescence in the 0.5 mg/ml with no signiﬁcant
difference between the 0.5 mg/ml and 0.28 mg/ml treatments and
no signiﬁcant difference between the 0.28 and 0.0625 mg/ml
treatments.
Representative histological images of the 1, 2 and 4 h incuba-
tions with rhodamine-labeled micelles and liposomes are pre-
sented in Fig. 3(C). At 2 and 4 h, micelles appeared to have diffused
across the superﬁcial and middle zones of articular cartilage. In
contrast, rhodamine-labeled liposome diffusion into the articular
cartilage was not observed.
Impact of IL-1 and trypsin treatments on diffusion of micelles and
liposomes in cartilage explants
Stimulationwith IL-1a has resulted in GAG depletion of cartilage
explants as evidenced by a signiﬁcant increase in GAG release from
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Fig. 3. Time and concentration-dependent association of rhodamine-labeled micelles
and liposomes with bovine cartilage explants. A: Absolute ﬂuorescence intensity
following incubation with 0.5 mg/ml rhodamine-labeled micelles or 0.5 mg/ml
rhodamine-labeled liposomes at 1, 2 and 4 h (n ¼ 12 in each group at each time points).
Data represent mean  SD. *Indicates that cartilage-associated ﬂuorescence following
incubation with micelles was signiﬁcantly higher (P < 0.001) than ﬂuorescence
following incubation with liposomes at 1 h. **Indicates that cartilage-associated
ﬂuorescence following incubation with micelles was signiﬁcantly higher (P ¼ 0.004)
than ﬂuorescence following incubation with liposomes at 2 h. *** Indicates that
K.A. Elsaid et al. / Osteoarthritis and Cartilage 21 (2013) 377e384 381cartilage explants into the culture media [Fig. 4(B)]. Representative
Alcian blue stained cartilage tissue demonstrated lack of staining in
the IL-1 treated explants. In contrast, native cartilage explants
demonstrated intense GAG staining [Fig. 4(B)]. Fluorescence
intensities of micelles and liposomes association with cartilage
explants following IL-1 or trypsin treatments were normalized to
control and are presented in Fig. 4(A) and (C), respectively.
Compared to control, and following IL-1 treatment, normalized
mean ﬂuorescence intensity with micelles treatment was 429.4%;
95% CI (349.0e509.8) while normalized mean ﬂuorescence with
liposomes was 132.0%, 95% CI (100.7e163.3). Normalized mean
ﬂuorescencewithmicelles in IL-1 treated explants was signiﬁcantly
higher (P < 0.001) than mean ﬂuorescence with micelles in control
explants. There was no signiﬁcant difference between mean ﬂuo-
rescence in control or IL-1 treated explants that were incubated
with liposomes. Following trypsin treatment, normalized mean
ﬂuorescence intensity with micelles treatment was 284.4%; 95% CI
(227.8e341.0) while normalized mean ﬂuorescence with liposomes
was 134.3%; 95% CI (105.0e163.7). Normalized mean ﬂuorescence
with micelles in trypsin-treated explants was signiﬁcantly higher
(P < 0.001) than mean ﬂuorescence with micelles in control
explants. There was no signiﬁcant difference between mean ﬂuo-
rescence in control or trypsin-treated explants that were incubated
with liposomes. Representative ﬂuorescence micrographs of
control, IL-1 and trypsin treated explants that were incubated with
rhodamine-labeledmicelles or liposomes are presented in Fig. 4(D).
Compared to control, IL-1 and trypsin treatments have resulted in
improved cartilage diffusion of micelles following 1 h incubation.
On the contrary, neither treatment has impacted the migration of
rhodamine-labeled liposomes in the articular cartilage even with
4 h of incubation.
Discussion
OA is a degenerative disease characterized by pathologic
changes to cartilage, synovium and subchondral bone12. A number
of potential disease targets, suitable for pharmacologic interven-
tions, have been identiﬁed13,14,15. A signiﬁcant proportion of these
targets reside intracellularly in chondrocytes or in the extracellular
matrix of cartilage. To successfully inhibit these disease pathways of
interest, DMOADs have to maintain effective synovial ﬂuid
concentration, diffuse through the different layers of cartilage and
distribute intracellularly into chondrocytes. Optimizing the rate
and extent of these kinetic processes (diffusion into cartilage and
cellular uptake) can signiﬁcantly improve the efﬁcacy of these
DMOADs.
We have evaluated the ability of micelles and liposomes (inert,
biocompatible and widely-used drug carriers) to associate with
chondrocytes. Micelles have shown an ability to associate with
chondrocytes compared to liposomes which did not show any
appreciable association. The cellular association of micelles was
rapid as seen at 1 h post-incubation with no signiﬁcant change tocartilage-associated ﬂuorescence following incubation with micelles was signiﬁcantly
higher (P < 0.001) than ﬂuorescence following incubation with liposomes at 4 h. B:
Concentration-dependent association of micelles with cartilage explants.
Fluorescently-labeled micelles were incubated at 0.50, 0.28 and 0.0625 mg/ml (n ¼ 12
in each group) with cartilage explants for 1 h at 37C followed by quantitative esti-
mation of cartilage-associated ﬂuorescence. Fluorescence intensity in the 0.28 mg/ml
and 0.0625 mg/ml groups were normalized to the 0.50 mg/ml concentration. Data
represent mean  SD. *Indicates that 0.0625 mg/ml concentration ﬂuorescence in the
superﬁcial layer of articular cartilage was signiﬁcantly lower (P ¼ 0.003) than 0.50 mg/
ml concentration. There was no signiﬁcant difference between the 0.50 mg/ml and
0.28 mg/ml concentrations. C: Representative ﬂuorescence micrographs of micelles
and liposomes association with cartilage explants following 1, 2 and 4 h. Scale bars
represent 0.2 mm.
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Fig. 4. Impact of IL-1a and trypsin treatments on rhodamine-labeled micelles and liposomes’ association with cartilage explants. A: Normalized ﬂuorescence intensity in control
and IL-1 stimulated bovine cartilage explants. Treatment with rhodamine-labeled micelles was performed using 0.5 mg/ml micelles and incubation for 1 h at 37C. Treatment with
rhodamine-labeled liposomes was performed using 0.5 mg/ml liposomes and incubation for 4 h at 37C. Data represent mean  SD. *Indicates that ﬂuorescence intensity in IL-1
treated explants incubated with rhodamine-labeled micelles (n ¼ 12) was signiﬁcantly higher (P < 0.001) than micelles-treated control explants (n ¼ 12). B: 7-day cumulative GAG
release of IL-1-stimulated and control bovine cartilage explants (n ¼ 12 in each group). *Indicates that cumulative GAG release was signiﬁcantly higher (P < 0.001) in the IL-1 group
compared to control. (a) Representative Alcian blue stained control bovine cartilage explants; (b) Representative Alcian blue stained IL-1-stimulated bovine cartilage explants. Scale
bars represent 0.2 mm. C: Impact of trypsin treatment on rhodamine-labeled micelle and liposome association with cartilage explants. Treatment with rhodamine-labeled micelles
was performed using 0.5 mg/ml micelles and incubation for 1 h at 37C. Treatment with rhodamine-labeled liposomes was performed using 0.5 mg/ml liposomes and incubation for
4 h at 37C. Data represent mean  SD. *Indicates that ﬂuorescence intensity in trypsin-treated explants incubated with rhodamine-labeled micelles (n ¼ 12) was signiﬁcantly
higher (P < 0.001) than micelles-treated control explants (n ¼ 12). D: Representative ﬂuorescence micrographs of micelles and liposomes association with cartilage explants in
untreated (control) explants, IL-1 treated and trypsin-treated explants. Scale bars represent 0.2 mm.
K.A. Elsaid et al. / Osteoarthritis and Cartilage 21 (2013) 377e384382the extent of this association at later time points. We have also
studied the impact of surface functionalization of micelles and
liposomes with a CPP on their chondrocyte association. Trans-
activating transcriptional activator (Tat) protein facilitates trans-
location of the human immunodeﬁciency virus (HIV-1) across cell
membrane16,17. TAT peptide is an arginine-rich, positively-charged
peptide derived from Tat protein and is the most-widely used
CPP18,19. TAT-conjugation was shown to efﬁciently improve cellular
uptake of a variety of nanoparticles, e.g. micelles, liposomes,dendrimers, gold and silver20,21,22,23,24. CPP conjugation of lipo-
somes and micelles improved their chondrocyte association. The
magnitude of improvement was higher with liposomes with an
estimated 8-fold improvement in cellular association compared to
unmodiﬁed liposomes. On the other hand, the magnitude of
enhancement in chondrocyte association of micelles following CPP
conjugation was approximately 3-fold. Nonetheless, CPP-modiﬁed
micelles exhibited the most signiﬁcant chondrocyte association
amongst the four formulations. TAT-conjugation to micelles or
K.A. Elsaid et al. / Osteoarthritis and Cartilage 21 (2013) 377e384 383liposomes did not adversely affect chondrocyte viability, an effect
that is consistent with other observations documenting the lack of
cytotoxic effect by the TAT peptide.
Cartilage is a dense avascular tissue and the rate of diffusion of
solutes and particles in cartilage is highly variable and depends on
factors e.g. particle size, concentration and extracellular matrix
composition25,26,27. In the bovine cartilage explant model, micelles
exhibited a time-dependent diffusion in articular cartilage. In
contrast, liposomes have shown no diffusion in articular cartilage.
This difference in diffusivity was observed as early as 1 h post
incubation and remained in the 4-h treatment. The 1-week IL-1a
treatment was used to simulate early cartilage OA changes. This is
characterized by GAG depletion with no signiﬁcant degenerative
change to the collagen network of the tissue28. We expected that
with GAG depletion, diffusion of micelles and liposomes will be
enhanced. Interestingly, only micelles exhibited a signiﬁcant
enhancement in their cartilage penetration. There was no
improvement in cartilage diffusion with liposomes following GAG
depletion. Subsequent to trypsin treatment, diffusion of micelles in
cartilage was also enhanced. Diffusion of liposomes into articular
cartilage was not impacted by trypsin treatment. Taken together,
these results point to the ability of micelles to diffuse into articular
cartilage and that this diffusion is enhanced by early degenerative
changes to articular cartilage.
The micelle and liposome formulations used in this study have
been well characterized over more than a decade of study in the
ﬁeld of pharmaceutical nanocarriers. The protocol reproducibly
yielded micelles of 15 nm effective diameter and liposomes of
138 nm effective diameter that are in agreement with literature-
reported values. The CPP-modiﬁcation resulted in a signiﬁcant
increase in the effective diameters of both carriers. The size
difference between unmodiﬁedmicelles and liposomes can be used
to partially explain differences seen in cartilage diffusivity.
However, size difference may not solely explain differential carti-
lage diffusion. Surface characteristics may play a role in the inter-
action of micelles and liposomes with cartilage. In this study,
micelles had a surface composed of polyethylene glycol that is more
hydrophilic than liposomes’ surface. It was evident that liposomes
were slower to associate with the top most layer of cartilage
compared to micelles. With 4 h of incubation, the ﬂuorescence
intensity of liposomes-associated cartilage remained lower than
the ﬂuorescence intensity of the 1-h micelles-associated cartilage.
The hydrophilic nature of lubricin, the large glycoprotein bound to
the surface of articular cartilage29, may explain this disparity
through favorable interaction with the more hydrophilic micelles.
Conversely, the phospholipids from the liposomal bilayer may
associate with the surface-associated phospholipids (SAPLs)30 in
the superﬁcial layer of articular cartilage, precluding further diffu-
sion. Thermodynamically, the PEG-PE monomers may prefer the
micellar conformation and hence continue to diffuse across the
superﬁcial zone into the middle zone of the cartilage. GAG deple-
tion signiﬁcantly enhanced diffusion of micelles into the middle
zone of articular cartilage. This is expected as removal of GAG,
a major extracellular matrix component, reduces steric hindrance
to particle movement. GAG removal did not signiﬁcantly enhance
diffusion of liposomes, providing more evidence that the barrier to
diffusion of liposomes into articular cartilage may be the nature of
the top-most superﬁcial layer of articular cartilage.
The difference in association of unmodiﬁed micelles and lipo-
somes with chondrocytes may be partially explained by their size
differences. Smaller size particles will probably better interact and
associate with chondrocytes’ cell membrane31. While CPP-
modiﬁcation enhanced chondrocyte association of both carrier
systems, a greater improvement was seen with liposomes. One
potential explanation of this difference is the number of CPP-residues per particle. The larger-surface liposomes would allow
a greater number of CPP-residues per particle compared to
micelles. A range of 1e4 CPP residues per particle is sufﬁcient to
confer cell penetrating properties, as previously reported19. We,
however, did not determine the speciﬁc number of residues per
particle as we had reasonable assurance that the molar ratio of our
conjugation procedure more than satisﬁes this threshold.
We have not evaluated the impact of CPP-surface modiﬁcation
and the resultant increase in effective particle diameters on carti-
lage explant diffusion of micelles. Therefore the effect of particle
size variation in the same nanocarrier platform on cartilage pene-
tration has not been assessed in this study. Another limitation to
this work is the in vitro nature of the experiments. Whether the
observed differences in chondrocyte association and cartilage
penetration between micelles and liposomes in the explant model
translates to in vivo differences following IA injection remains to be
studied. Previous in vivo experiments performed with liposomes in
rheumatoid arthritis (RA) animal models suggest that liposomes
are predominantly uptaken by the inﬂamed synovium32,33. While
this is clinically valuable in RA, our work suggests that liposomes
may not be a suitable drug carrier platform to target articular
cartilage and thus of limited value in OA. The novelty of our work
lies in the use of a widely-established explant model coupled with
isolated chondrocyte culture to study their interaction with
different pharmaceutical platforms. This model can be used to
understand the effect of surface modiﬁcation, size and surface
charge of various nanocarriers on diffusion in, and association with
articular cartilage. Using the explants model, we were able to
demonstrate that micelles, either modiﬁed or unmodiﬁed, appear
to be a suitable drug carrier platform to deliver cartilage-targeted
intracellular poorly soluble drugs and thus warrant their further
development as a drug delivery platform for OA.
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